Authors : Dr. Keerthana; Dr. Ningappa Karalingannavar; Dr. Bhagyashri Patil; Dr. Gajanan S. Gaude; Dr. Jyothi Hattiholi; Dr. Gautam S.; Dr. Kirankumar Pujar

Volume/Issue : Volume 10 - 2025, Issue 3 - March

Google Scholar : https://tinyurl.com/map96j8u

Scribd : https://tinyurl.com/wa6b74s4

DOI : https://doi.org/10.38124/ijisrt/25mar1257

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Background: Extraskeletal Ewing’s sarcoma (EES) is a rare and aggressive small round cell tumor, primarily affecting soft tissues outside the skeletal system. Pulmonary involvement is uncommon, and hemorrhagic pleural effusion as an initial presentation is exceedingly rare. Due to its rarity, EES is often misdiagnosed, particularly in endemic regions where tuberculosis is prevalent.  Case Presentation: We report a case of a 33-year-old female with no known comorbidities who presented with progressive breathlessness, chest pain, and chronic dry cough for three months. She also reported intermittent fever and unintentional weight loss. Initial imaging suggested a right-sided pleural effusion, which was hemorrhagic on thoracentesis. Pleural fluid analysis revealed an exudative effusion with a lymphocyte-predominant cytology but was negative for malignancy. A contrast- enhanced CT (CECT) thorax demonstrated a large heterogeneously enhancing mass involving the parietal pleura, with adjacent rib erosion. Pleural biopsy and immunohistochemistry confirmed the diagnosis of EES. The patient was initiated on combination chemotherapy, resulting in a significant reduction in tumor size on follow-up imaging.  Conclusion: EES should be considered in young adults presenting with unexplained hemorrhagic pleural effusions. Early recognition and histopathological confirmation are critical for timely intervention. Multimodal therapy, including chemotherapy, surgical excision, and radiotherapy, remains the mainstay of treatment.

References :

1. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. J Clin Oncol. 2011;29(17):2308-2314.
2. Gupta AA, Pappo A, Saunders N, et al. Clinical management of extraskeletal Ewing sarcoma. Pediatr Blood Cancer. 2015;62(2):214-217.
3. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing’s Sarcoma: Current Management and Future Approaches. Sarcoma. 2011;2011:1-7.
4. Ladenstein R, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-3291.
5. Karski EE, Matthay KK, Neuhaus J, et al. Prognostic factors in Ewing sarcoma family tumors. Pediatr Blood Cancer. 2013;60(12):2046-2052.
6. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma. N Engl J Med. 2003;348(8):694-701.
7. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006;11(5):503-519.